6 June 2007

Annual General Meeting

“Cyprotex continues to build momentum and reputation within its global pharmaceutical client base. Such endorsement underlines the Group’s position at the technological forefront of ADME/Tox screening, whilst recognising the opportunity of the international market place it addresses.

The extraordinary general meeting that was called earlier this year by a group of ‘Requisitionists’ intent on unseating the present management was overwhelmingly defeated. Despite causing a very unnecessary and costly diversion of resources for your company, the Board took rapid action to ensure that progress during the first six months of 2007 was not derailed.

At this time, Cyprotex appears to be ending the first half on a strong note. Moreover, the continued expansion of its customer base and anticipation of deepening collaboration opportunities within the ‘Top Ten’ global giants bodes very well for the second half.”

For further information:

Cyprotex PLC
Robert Morrison Atwater, CEO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Code Securities Limited
Charles Walker, Corporate Finance
Tel: +44 (0)20 7776 1200
cic@codesecurities.com
www.codesecurities.com

Media Enquires:

WMC Communications
Alex Glover
Tel: +44 (0)20 7930 9030
alex.glover@wmccommunications.com